BioForce Nanosciences (OTCMKTS:BFNH) and BioCryst Pharmaceuticals (NASDAQ:BCRX) Head-To-Head Analysis

BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioForce Nanosciences (OTCMKTS:BFNH) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and BioForce Nanosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84 million	2.79	$263.86 million	($1.50)	-6.37
BioForce Nanosciences	N/A	N/A	-$1.29 million	$0.01	365.20

BioCryst Pharmaceuticals has higher revenue and earnings than BioForce Nanosciences. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than BioForce Nanosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioCryst Pharmaceuticals and BioForce Nanosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
BioForce Nanosciences	N/A	-84.67%	-16.36%

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, BioForce Nanosciences has a beta of -0.52, suggesting that its share price is 152% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for BioCryst Pharmaceuticals and BioForce Nanosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0	4	8	0	2.67
BioForce Nanosciences	0	0	0	0	0.00

BioCryst Pharmaceuticals presently has a consensus target price of $20.60, suggesting a potential upside of 115.48%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than BioForce Nanosciences.

Institutional and Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 39.5% of BioForce Nanosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BioCryst Pharmaceuticals beats BioForce Nanosciences on 8 of the 13 factors compared between the two stocks.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

About BioForce Nanosciences

BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels. BioForce Nanosciences Holdings, Inc. is based in Virginia Beach, Virginia.